552c7ae14ClaimWithout environmental regulations to ensure safety, people will become sickAgreeDisagree
552c7ae14ClaimA lack of environmental regulations makes people sick, which in turn reduces their productivityAgreeDisagree
552c7ae14ClaimThe mathematical backing for the public health benefits of stricter environmental regulation is shakyAgreeDisagree
552c7ae14ClaimMajor outbreaks of waterborne or foodborne illnesses are not largely occurring in the United StatesAgreeDisagree
552c7ae14ClaimIn the United States, environmental regulations have reached a point of diminishing returns for public health benefitsAgreeDisagree
552c7ae14ClaimThe focus of public health efforts should be on preventing diseases rather than treating themAgreeDisagree
552c7ae14ClaimOver the longer term, stricter environmental regulation impacts susceptible populations more than it contributes to public healthAgreeDisagree
552c7ae14ClaimStricter environmental regulation has a greater negative impact on susceptible populations than the public health benefits it providesAgreeDisagree
552c7ae14ClaimSickness resulting from a lack of environmental regulation leads to treatment costsAgreeDisagree
552c7ae14ClaimSatralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signalingAgreeDisagree
552c7ae14ClaimThyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidismAgreeDisagree
552c7ae14ClaimSatralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye diseaseAgreeDisagree
552c7ae14ClaimPrior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026AgreeDisagree
552c7ae14ClaimSatralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory conditionAgreeDisagree
552c7ae14ClaimSatralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare providerAgreeDisagree
552c7ae14ClaimAlthough satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2AgreeDisagree